Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
BACKGROUND
Visceral hypersensitivity plays a major role in the pathophysiology of irritable bowel syndrome, as shown by balloon distension studies. 5-HT3 receptors on afferent nerves may modulate visceral sensitivity and be the target of new treatments for irritable bowel syndrome.


OBJECTIVE
To evaluate the effects of alosetron, a potent and selective 5-HT3 antagonist, on the perception of colonic distension by patients with irritable bowel syndrome, and on the colonic compliance to distension with a barostat.


METHODS
Twenty-five irritable bowel syndrome patients were included in a randomized double-blind parallel group trial; data were available for 22 (Rome criteria; 48 +/- 11 years: 13 men and nine women). Patients were treated for 7 days with placebo (n = 6), alosetron 0.25 mg b.d. (n = 8) or alosetron 4 mg b.d. (n = 8). On day 6, a barostat bag was placed in the left colon. On day 7, after an overnight fast, isobaric phasic distensions were performed (4 mmHg steps, 5 min) up to the step triggering a sensation of abdominal pain.


RESULTS
Groups were comparable at inclusion (age, sex, symptoms, bowel habits). There were no differences between treatment groups in pressure recorded within the bag at the time of first sensation of abdominal pain. However, bag volumes were significantly increased. At the first sensation threshold, median volume differences of 61 mL and 90 mL (P = 0.028) were recorded with alosetron 0.25 mg b.d. and 4 mg b.d., respectively. At the threshold of abdominal pain, these differences were 71 mL (P = 0.039) and 84 mL (P = 0.017). Colonic compliance increased from 5.9 mL/mmHg on placebo to 7.6 mL/mmHg on alosetron 0.25 mg b.d. and to 9.8 mL/mmHg (P = 0.034) on alosetron 4 mg b.d.


CONCLUSIONS
Alosetron increases the compliance of the colon to distension, and could thereby contribute to changes in perception of colonic distension and improvement in the symptoms of irritable bowel syndrome.
Laboratory of Digestive Motility, Gastroenterology Unit, Toulouse, France. 106521.3337@compuserve.com
M
M
Delvaux
D
D
Louvel
J P
JP
Mamet
R
R
Campos-Oriola
J
J
Frexinos
D000328:Adult; D002243:Carbolines / Q000627:therapeutic use*; D003106:Colon / Q000187:drug effects* / Q000502:physiology; D003109:Colonic Diseases, Functional / Q000188:drug therapy* / Q000503:physiopathology; D003187:Compliance; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017288:Pain Threshold / Q000187:drug effects; D017699:Pelvic Pain / Q000188:drug therapy; D010465:Perception / Q000187:drug effects; D012702:Serotonin Antagonists / Q000627:therapeutic use*
D002243:Carbolines; D012702:Serotonin Antagonists; C090840:alosetron